Scarica l'app Stockscreener
4.87
2.96%
0.14
Dopo l'orario di chiusura:
5.08
0.21
+4.31%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GLUE Giù?
Forum
Previsione
Precedente Chiudi:
$4.73
Aprire:
$4.79
Volume 24 ore:
198.24K
Relative Volume:
0.31
Capitalizzazione di mercato:
$312.47M
Reddito:
-
Utile/perdita netta:
$-130.41M
Rapporto P/E:
-2.1741
EPS:
-2.24
Flusso di cassa netto:
$-67.76M
1 W Prestazione:
+4.51%
1M Prestazione:
+4.96%
6M Prestazione:
-32.08%
1 anno Prestazione:
+25.19%
Intervallo 1D:
$4.64
$4.88
Intervallo di 1 settimana:
$4.42
$4.88
Portata 52W:
$3.5001
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Nome
Monte Rosa Therapeutics Inc
Settore
Industria
Telefono
617-949-2643
Indirizzo
321 HARRISON AVENUE, BOSTON
Confronta GLUE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
4.87 | 312.47M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Iniziato | UBS | Buy |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-10-14 | Iniziato | SVB Leerink | Mkt Perform |
Mostra tutto
Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie
Monte Rosa gets FDA clearance to begin testing MRT-8102 - MSN
FMR LLC Reduces Stake in Monte Rosa Therapeutics Inc. - GuruFocus
Bank of America Corp DE Reduces Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa’s molecular glue degrader MRT-8102 gains IND clearance for inflammatory conditions - BioWorld MedTech
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stake Boosted by Millennium Management LLC - Defense World
Monte Rosa advances novel inflammatory disease treatment By Investing.com - Investing.com South Africa
Monte Rosa Therapeutics Says US FDA Accepts Investigational New Drug Application for MRT-8102 - marketscreener.com
Monte Rosa Therapeutics, Inc. Announces FDA Clearance of IND Application for MRT-8102, A NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - MarketScreener
Monte Rosa Therapeutics (GLUE) Gains as FDA Clears New Drug Tria - GuruFocus
Monte Rosa gets FDA clearance to begin testing MRT-8102 (GLUE) - Seeking Alpha
Monte Rosa Therapeutics (GLUE) Gains FDA Approval for MRT-8102 I - GuruFocus
Monte Rosa advances novel inflammatory disease treatment - Investing.com
Monte Rosa Therapeutics Announces FDA Clearance Of Ind Application For Mrt-8102 - MarketScreener
Monte Rosa Therapeutics Announces FDA Clearance of IND - GlobeNewswire
FDA Clearance: Monte Rosa's Revolutionary NEK7 Drug Could Transform Inflammatory Disease Treatment - Stock Titan
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet - sharewise
Two Sigma Advisers LP Takes $180,000 Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Sold by Jane Street Group LLC - Defense World
Squarepoint Ops LLC Takes Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
6,231 Shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Acquired by BNP Paribas Financial Markets - Defense World
ProShare Advisors LLC Buys New Shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Deutsche Bank AG Buys 6,633 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Purchased by Two Sigma Investments LP - Defense World
CDK2 degradation inducers disclosed in Monte Rosa patent - BioWorld MedTech
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Monte Rosa CEO Reveals Latest Molecular Glue Degrader Progress at Major Healthcare Conference - Stock Titan
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and Aptose Biosciences (NASDAQ:APTO) - Defense World
D. E. Shaw & Co. Inc. Raises Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Holdings Increased by Northern Trust Corp - Defense World
Revenues Working Against Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Share Price Following 26% Dive - simplywall.st
Dimensional Fund Advisors LP Has $1.01 Million Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stake Increased by Tower Research Capital LLC TRC - Defense World
Results: Monte Rosa Therapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit - simplywall.st
Monte Rosa Therapeutics Inc (GLUE)’s Day in Review: Closing at 4.22, Up by 9.61 - DWinneX
Monte Rosa Therapeutics: Q1 Earnings Snapshot - New Haven Register
Barclays PLC Raises Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics Reports Strong Q1 2025 Earnings - TipRanks
Monte Rosa Therapeutics Reports Strong Q1 2025 Results - MSN
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates - MSN
Monte Rosa Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MONTE ROSA THERAPEUTICS Earnings Results: $GLUE Reports Quarterly Earnings - Nasdaq
Monte Rosa Therapeutics (GLUE) Advances Novel Therapeutic Progra - GuruFocus
Monte Rosa Therapeutics, Inc. SEC 10-Q Report - TradingView
Invesco Ltd. Purchases New Shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics Inc Azioni (GLUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Monte Rosa Therapeutics Inc Azioni (GLUE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Leo Chandra P. | Director |
Mar 24 '25 |
Buy |
5.84 |
10,000 |
58,383 |
10,000 |
| Versant Venture Capital VI, L. | 10% Owner |
Oct 28 '24 |
Sale |
9.66 |
89,990 |
869,240 |
2,007,948 |
| Versant Venture Capital VI, L. | 10% Owner |
Oct 29 '24 |
Sale |
9.16 |
67,905 |
621,801 |
1,573,453 |
0.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):